.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Chinese Patent Office
Farmers Insurance
US Department of Justice
Federal Trade Commission
Daiichi Sankyo
Mallinckrodt
Harvard Business School
Covington
Novartis

Generated: December 15, 2017

DrugPatentWatch Database Preview

Fresenius Medcl Company Profile

« Back to Dashboard

What is the competitive landscape for FRESENIUS MEDCL, and what generic alternatives to FRESENIUS MEDCL drugs are available?

FRESENIUS MEDCL has nine approved drugs.

There are five US patents protecting FRESENIUS MEDCL drugs.

There are twenty-two patent family members on FRESENIUS MEDCL drugs in seventeen countries and thirty-seven supplementary protection certificates in ten countries.

Summary for Fresenius Medcl

International Patents:22
US Patents:5
Tradenames:22
Ingredients:5
NDAs:9
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Fresenius MedclDELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINERcalcium chloride; dextrose; magnesium chloride; sodium chloride; sodium lactateSOLUTION;INTRAPERITONEAL018883-002Nov 30, 1984ATRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Fresenius MedclDELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINERcalcium chloride; dextrose; magnesium chloride; sodium chloride; sodium lactateSOLUTION;INTRAPERITONEAL020171-002Aug 19, 1992ATRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Fresenius MedclDELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINERcalcium chloride; dextrose; magnesium chloride; sodium chloride; sodium lactateSOLUTION;INTRAPERITONEAL018379-006Jul 7, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Fresenius MedclDELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINERcalcium chloride; dextrose; magnesium chloride; sodium chloride; sodium lactateSOLUTION;INTRAPERITONEAL020171-001Aug 19, 1992ATRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Fresenius MedclINPERSOL-ZM W/ DEXTROSE 2.5% IN PLASTIC CONTAINERcalcium chloride; dextrose; sodium chloride; sodium lactateSOLUTION;INTRAPERITONEAL019395-002Mar 26, 1986DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Fresenius MedclDELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINERcalcium chloride; dextrose; magnesium chloride; sodium chloride; sodium lactateSOLUTION;INTRAPERITONEAL018379-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Fresenius MedclPHOSLOcalcium acetateCAPSULE;ORAL021160-001Apr 2, 2001DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Fresenius MedclINPERSOL-ZM W/ DEXTROSE 1.5% IN PLASTIC CONTAINERcalcium chloride; dextrose; sodium chloride; sodium lactateSOLUTION;INTRAPERITONEAL019395-001Mar 26, 1986DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Fresenius MedclDELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINERcalcium chloride; dextrose; magnesium chloride; sodium chloride; sodium lactateSOLUTION;INTRAPERITONEAL018883-003Nov 30, 1984ATRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Fresenius MedclDELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINERcalcium chloride; dextrose; magnesium chloride; sodium chloride; sodium lactateSOLUTION;INTRAPERITONEAL018379-008Jun 24, 1988DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Fresenius Medcl

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Fresenius MedclPHOSLOcalcium acetateCAPSULE;ORAL021160-001Apr 2, 2001► Subscribe► Subscribe
Fresenius MedclPHOSLOcalcium acetateTABLET;ORAL019976-001Dec 10, 1990► Subscribe► Subscribe
Fresenius MedclPHOSLO GELCAPScalcium acetateCAPSULE;ORAL021160-003Apr 2, 2001► Subscribe► Subscribe
Fresenius MedclPHOSLOcalcium acetateCAPSULE;ORAL021160-002Apr 2, 2001► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for FRESENIUS MEDCL drugs

Drugname Dosage Strength Tradename Submissiondate
calcium acetateOral Solution667 mg/5 mLPHOSLYRA12/5/2013
calcium acetateCapsulesEQ 169 mg calciumPHOSLO5/31/2005

International Patent Family for Fresenius Medcl Drugs

Country Document Number Estimated Expiration
Mexico2009000722► Subscribe
European Patent Office2048948► Subscribe
Poland2048948► Subscribe
China101522021► Subscribe
Austria547099► Subscribe
New Zealand574331► Subscribe
Hong Kong1202815► Subscribe
South Korea20090040340► Subscribe
Spain2382993► Subscribe
China104095838► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Fresenius Medcl Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB07/011United Kingdom► SubscribePRODUCT NAME: GADOFOSVESET TRISODIUM; REGISTERED: UK EU/1/05/313/001 20051003; UK EU/1/05/313/002 20051003; UK EU/1/05/313/003 20051003; UK EU/1/05/313/004 20051003; UK EU/1/05/313/005 20051003; UK EU/1/05/313/006 20051003; UK EU/1/05/313/007 20051003; UK EU/1/05/313/008 20051003; UK EU/1/05/313/009 20051003
C/GB02/042United Kingdom► SubscribePRODUCT NAME: ERTAPENEM ((1R,5S,6S,8R,2'S,4'S)-2-(2-(3-CARBOXYPHENYLCARBAMOYL)PYRROLIDIN-4-YLTHIO)-6-(1-HYDROXYETHYL)-1-METHYLCARBAPENEM-3-CARBOXYLIC ACID), A PHARMACEUTICALLY ACCEPTABLE SALT OR IN VIVO HYDROLYSABLE ESTER THEREOF, ESPECIALLY AS THE MONOSODIUM SALT ERTA; REGISTERED: UK EU/1/02/216/001 20020418
00125Netherlands► SubscribePRODUCT NAME: ROSUVASTATINUM, DESGEWENST IN DE VORM VAN EEN NIET-TOXISCH FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET CALCIUMZOUT; REGISTRATION NO/DATE: RVG 26872 - RVG 26874 20021106
C/GB00/021United Kingdom► SubscribePRODUCT NAME: (1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE)BIS(PHOSPHONIC ACID) "RESIDRONATE" AND SALTS THEREOF, ESPECIALLY THE SODIUM SALT; REGISTERED: SE 15296 19991007; SE 15297 19991007; UK PL 00364/0070 20000316
C0022France► SubscribePRODUCT NAME: MONTELUKAST SODIUM; REGISTRATION NO/DATE IN FRANCE: NL 23 133 DU 19980320; REGISTRATION NO/DATE AT EEC: 13 651 DU 19970825
C0108Belgium► SubscribePRODUCT NAME: MANGAFODIPIR TRISODIUM (ANHYDROUS) CORRESP. MANGAFODIPIR; REGISTRATION NO/DATE: EU/1/97/040/001 19970522
C0021France► SubscribePRODUCT NAME: PEGAPTANIB SODIUM; REGISTRATION NO/DATE: EU/1/05/325/001 20060131
C/GB98/025United Kingdom► SubscribePRODUCT NAME: MONTELUKAST, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREFERABLY MONTELUKAST SODIUM; REGISTERED: FI 12766 19970825; FI 12767 19970825; UK 00025/0357 19980115; UK 00025/0358 19980115
2008006Lithuania► SubscribePRODUCT NAME: FOSAMPRENAVIR CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001-002 20040712
C/GB03/033United Kingdom► SubscribePRODUCT NAME: ROSUVASTATIN OPTIONALLY IN THE FORM OF A NON-TOXIC PHARMACEUTICALLY ACCEPTABLE SALT, PARTICULARLY THE CALCIUM SALT.; REGISTERED: NL 26872 20021106; NL 26873 20021106; NL 26874 20021106; UK PL 17901/0201 20030321; UK PL 17901/0202 20030321; UK PL 17901/0203 20030321
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
UBS
Healthtrust
US Department of Justice
Chubb
Covington
McKesson
Julphar
Boehringer Ingelheim
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot